What's new? Log in Free sign up

BriaCell Therapeutics (BCTX) News and press releases

Company Profile

News

From Benzinga Pro

BriaCell Therapeutics Granted U.S. Patent# 11559574: Whole-cell Cancer Vaccines And Methods For Selection Thereof

https://www.scribd.com/document/621627063/BCTX-Patent

BriaCell CEO Letter To Shareholders

Biotech, News, Guidance, FDA, General

Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization. Successful completion of the

BriaCell To Investigate Alleged Illegal Trading Of Public Securities

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced today

BriaCell Announces End Of Phase II Meeting With FDA For Bria-IMT Combination In Advanced Metastatic Breast Cancer; FDA Has Agreed On Primary Endpoint

Biotech, News, FDA, General

BriaCell has received agreement and positive feedback from its End of Phase II meeting with the FDA for lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor, in advanced metastatic breast

BriaCell Announces New Patent Issuance, Bria-OTS IND Timing Guidance, And Additional Clinical Sites To Boost Enrolment

Biotech, News, FDA, General

BriaCell's new patent protects its novel personalized off-the-shelf cell-based technology for breast cancer and multiple other cancer indications until 2040. BriaCell expects to initiate its Bria-OTS™

IPA's Subsidiary BioStrand And BriaCell Announce Artificial Intelligence Collaboration And License Agreement To Discover And Develop Anti-Cancer Antibodies

Biotech, General

IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ:IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV ("BioStrand"), an AI in

Earlier Reported, BriaCell CEO Discusses Clinical Results Of Its Breast Cancer Immunotherapy Treatment In An Audio Interview With SmallCapVoice.com

Biotech, News, FDA, Events, General

SmallCapVoice.com Inc. ("SCV") announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp.

BriaCell To Present Breast Cancer Efficacy Data With Bria-IMT Immunotherapy Treatment At SITC Annual Meeting

Biotech, General

Bria-IMT™ regimen in combination with Incyte's retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell's recent 12 patient cohort in advanced

Press releases

From Benzinga Pro

BriaCell CEO Letter to Shareholders

News, Health Care, Management, Press Releases

Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization.Successful completion of the

BriaCell to Investigate Alleged Illegal Trading of Public Securities

Markets, Press Releases

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company

BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer

Health Care, Press Releases

BriaCell has received agreement and positive feedback from its End of Phase II meeting with the FDA for lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor, in advanced metastatic breast

BriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment

News, Health Care, Legal, Press Releases

BriaCell's new patent protects its novel personalized off-the-shelf cell-based technology for breast cancer and multiple other cancer indications until 2040.BriaCell expects to initiate its Bria-OTS™ clinical

BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients

By Ernest Dela Aglanu, BenzingaWest Vancouver, BC--News Direct--Small and big pharma companies such as Pfizer Inc. (NYSE:PFE), Celldex Therapeutics Inc. (NASDAQ:CLDX), and Hologic Inc. (NASDAQ:HOLX) are ramping up

BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®

Positive clinical data reported includes tumor shrinkage, disease control, progression free survival, and potential long term survival benefit in advanced metastatic breast cancer patients treated with the

BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients

By Faith Ashmore, BenzingaWest Vancouver, BC--News Direct--The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the

IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ:IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV ("BioStrand"), an AI in silico discovery subsidiary of IPA, has